CONTACT PERSON: Dr. Ron Dirks
TELEPHONE: +31 (0) 71 332 2270
ZF-screens is a spin-off company from Leiden University that has developed patented technology for the automated in vivo high-throughput screening of pharmaceutical drug candidates against diseases. This is achieved through novel robotic screens using model systems such as zebrafish. Currently the main focus is on high-throughput technologies for biomedical screens in the areas of cancer research and infectious diseases.
Their technologies include state-of-the-art genetic tools. ZFS is co-owner of an Illumina HiSeq2500 sequencer and has multiple years of experience with de novo vertebrate genome assembly and gene expression profiling based on mRNA-Seq analysis. ZFS is also among the first users of the revolutionary new Nanopore Sequencing technology (Oxford Nanopore's MinION). ZFS has participated in several national and international projects, including the Dutch Smart Mix project and the EU projects ZF-Tools and ZF-Cancer, is partner in the IMI project PreDict-TB and performs contract research.
Role in the project:
ZF-screens will have a key role in genomics and transcriptomics analysis of host-parasite interactions (WP1), including de novo parasite genome assemblies and biomarker discovery. In addition, ZF-screens will participate in developing screening platforms for new effective drugs against parasitic diseases (WP5).
Key persons involved:
|Dr. Ron Dirks is a molecular biologist and managing director of ZF-screens. He manages several projects involved in high-throughput drug screening platforms in zebrafish larvae, de novo assembly of vertebrate genomes, and artificial maturation of aquaculture fish. He has more than 40 peer-reviewed publications.|
|Dr. Hans Jansen is laboratory manager and an expert in Illumina sequencing and in vivo high-throughput screening technology. He has more than 30 peer-reviewed publications.|
|Ing. Susanne Jong-Raadsen is technician with multiple years of experience in zebrafish larvae high-throughput screening technology and Next Generation sequencing.|
|Dr. Peter Racz is an expert in zebrafish larvae toxicology and developing alternative animal models for pharmaceutical and toxicological purposes (NC3R).|